Completed PHASE4 INTERVENTIONAL 2-arm NCT01195194

Selection of Immunosuppression in Kidney Transplant Recipients Depending on Pre-transplant Donor-specific T-cell Reactivity. (SIRES)

Pilot Study of Selection of Either Calcineurin Inhibitor(CNI)-Based or CNI-free Immunosuppressive Regimen Depending on the Result of Pre-transplantation Donor-specific T-cell Reactivity Measured by Enzyme-linked Immunosorbent Spot(ELISPOT) in Standard-risk Kidney Recipients.

Sponsor: Carlos III Health Institute

Conditions Disorder Related to Renal Transplantation

Interventions PRE-TRANSPLANT (PRE=before)

Updated 5 times since 2017 Last updated: Feb 24, 2014 Started: Mar 31, 2008 Primary completion: Jun 30, 2012 Completion: Jun 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Disorder Related to Renal Transplantation and is currently completed. Carlos III Health Institute leads this study, which shows 5 recorded versions since 2008 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Mar 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Carlos III Health Institute
Josep M Grinyo

Data source: Hospital Universitari de Bellvitge

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Barcelona, Spain
• L'Hospitalet de Llobregat, Spain